Accuray wins CE mark for new helical radiation delivery system

Accuray (Nasdaq: ARAY)+ announced today that it received CE mark approval for its Helix CT-guided helical radiotherapy system.

The Madison, Wisconsin-based company designed Helix to deliver high performance and high throughput in radiotherapy. It developed the new system for emerging markets in which access to advanced cancer care — including radiotherapy — is typically obtainable only within urban areas. These areas have an availability of linear accelerators per million population well under World Health Organization recommended guidelines. The company labeled India as a priority due to this disparity as well.

Accuray Helix provides a solution for clinical teams requiring short treatment times and cost-effectiveness. The company wants to establish a care path for patients in non-urban communities who previously faced limited options

Sign up for Blog Updates